Johnson & Johnson (JNJ) Receives ‘Analyst’ Rating

Johnson & Johnson (JNJ) : The consensus on Johnson & Johnson (JNJ) based on 18 analyst recommendation on the company stock is 2.11, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Johnson & Johnson (JNJ) : 13 Wall Street analysts covering Johnson & Johnson (JNJ) believe that the average level the stock could reach for the short term is $123.77. The maximum price target given is $142 and the minimum target for short term is around $81, hence the standard deviation is calculated at $17.01.


Also, Equity analysts at the Brokerage firm Jefferies maintains its rating on Johnson & Johnson (NYSE:JNJ). The rating major has initiated the coverage with hold rating on the shares. The Analysts at Jefferies raises the price target from $113 per share to $119 per share. The rating by the firm was issued on August 4, 2016.

Johnson & Johnson (NYSE:JNJ): After opening at $117.81, the stock dipped to an intraday low of $117.32 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $118.94 and the buying power remained strong till the end. The stock closed at $118.63 for the day, a gain of 0.65% for the day session. The total traded volume was 5,814,900. The stocks close on the previous trading day was $117.86.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.